Axovant Sciences Ltd.
Clarendon House
2 Church Street
Hamilton
HM 11
Website: http://www.axovant.com/
Email: info@axovant.com
121 articles about Axovant Sciences Ltd.
-
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
-
Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, A Novel Gene Therapy for Patients with Parkinson’s Disease
10/25/2018
Initial data from the first cohort expected in first half of 2019
-
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found. The U.S. Centers for Disease Control and Prevention published a new report in the journal Alzheimer’s & Dementia projecting the disease’s likely expansion, and for the firs...
-
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
-
Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval
8/28/2018
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
-
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
-
Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant
7/9/2018
Benitec Biopharma Limited announced that it has licensed to Axovant Sciences ("Axovant") the exclusive global rights for BB-301
-
Axovant, one of Vivek Ramaswamy’s biotech companies best known for its catastrophic Alzheimer’s failure in September 2017, is replenishing its pipeline with a licensing deal with Australian company Benitec Biopharma.
-
Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.
-
Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease
6/6/2018
~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below)
-
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
-
After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.
-
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
-
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
-
Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.
-
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
-
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
-
The news was revealed in a filing with the SEC.
-
Axovant shares plunged after Hung abruptly resigned as CEO and also stepped down from his seat on the company board of directors.
-
With the J.P. Morgan Healthcare Conference now over, some analysts are looking back and picking out the "winners and losers" from the conference.